News Related to aromatase inhibitor

Related coverage linked through entity extraction aliases.

Breast Cancer Treatment Side Effects: Cardiotoxicity and Bone Health Challenges

Mar 13, 2026

Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.

FDA Reviews Giredestrant Plus Everolimus for ESR1-Mutated ER-Positive Breast Cancer

Feb 20, 2026

The FDA has accepted a new drug application for giredestrant plus everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with a decision expected by December 18, 2026. The phase 3 evERA study showed a 62% reduction in disease progression or death risk in ESR1-mutated patients.